Mechanisms involved in the development of chronic Hepatitis C as potential targets of antiviral therapy

Current Pharmaceutical Biotechnology

Volumn 12, Issue 11, 2011, Pages 1774-1780

  Jackowiak, Paulina ^a   Figlerowicz, Magdalena ^b   Kurzyńska Kokorniak, Anna ^a   Figlerowicz, Marek ^a,c  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c POZNAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Antiviral therapy; CD81; Chronic hepatitis C; Error catastrophe; Genetic variability; HCV; miR 122; Molecular

Indexed keywords

A 837093; ABT 450; ANTIVIRUS AGENT; AZACITIDINE; BALAPIRAVIR; BI 207127; BOCEPREVIR; CD81 ANTIGEN; CYTOCHROME P450 2D6; DANOPREVIR; FILIBUVIR; FLUOROURACIL; GLYCOPROTEIN E2; GLYCOPROTEIN IIIA; IDX 320; IDX 375; IMMUNOGLOBULIN G; MERICITABINE; MICRORNA; MICRORNA 122; PEGINTERFERON; PSI 7851; RIBAVIRIN; TEGOBUVIR; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN; VIRUS RNA;

5' UNTRANSLATED REGION; ANTIVIRAL THERAPY; ARTICLE; DRUG POTENTIATION; DRUG TARGETING; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOLECULAR MIMICRY; RNA REPLICATION; VIRUS GENOME; VIRUS REPLICATION;

EID: 83455235218     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798377030     Document Type: Article

References (83)

1. WHO, Hepatitis C - global prevalence (update), Weekly Epidemiological Record, 1999; pp. 425-427.
2. Castellano, G. The natural history of hepatitis C virus infection. Nephrol. Dial. Transplant., 2000, 15 (Suppl. 8), 19-23.
3. Choo, Q.L.; Kuo, G.; Weiner, A.J.; Overby, L.R.; Bradley, D.W.; Houghton, M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science, 1989, 244, 359-362.
4. Forns, X.; Bukh, J.; Purcell, R.H. The challenge of developing a vaccine against hepatitis C virus. J. Hepatol., 2002, 37, 684-695.
5. Gagneten, S.; Feinstone, S. In: Hepatitis C, Biomedical Research Report; Galin, I. and Fauci, A., Eds.; Academic Press, San Diego, USA, 2000; pp. 469-486.
6. Pearlman, B.L. Hepatitis C treatment update. Am. J. Med., 2004, 117, 344-352.
7. Gerlach, T.J.; Zachoval, R.; Gruener, N.; Jung, M.-C.; Ulsenheimer, A.; Schraut, W.; Schirren, A.; Waechtler, M.; Backmund, M.; Diepolder, H.; G. P. A cute hepatitis C: natural course and response to antiviral treatment. Hepatology, 2001, 34, A341.
8. Chen, S.L.; Morgan, T.R. The natural history of hepatitis C virus (HCV) infection. Int. J. Med. Sci., 2006, 3, 47-52.
9. Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; Rustgi, V.K.; Shiffman, M.; Reindollar, R.; Goodman, Z.D.; Koury, K.; Ling, M.; Albrecht, J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001, 358, 958-965.
10. McHutchinson, J.G.; Hoofnagle, J.H. Therapy of chronic hepatitis C. in: T.J. Liang, and J.H. Hoofnagle, Eds., Hepatitis C, Academic Press, San Diego, California, USA, 2000, pp. 203-239.
11. Lohmann, V.; Korner, F.; Koch, J.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 1999, 285, 110-113.
12. Horscroft, N.; Lai, V.C.; Cheney, W.; Yao, N.; Wu, J.Z.; Hong, Z.; Zhong, W. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir. Chem. Chemother., 2005, 16, 1-12.
13. Soriano, V.; Peters, M.G.; Zeuzem, S. New therapies for hepatitis C virus infection. Clin. Infect. Dis., 2009, 48, 313-320.
14. Melnikova, I. Hepatitis C therapies. Nat. Rev. Drug. Discov., 2008, 7, 799-800.
15. Martell, M.; Esteban, J.I.; Quer, J.; Genesca, J.; Weiner, A.; Esteban, R.; Guardia, J.; Gomez, J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol., 1992, 66, 3225-3229.
16. Figlerowicz, M.; Alejska, M.; Kurzyńska-Kokorniak, A.; Figlerowicz, M. Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections. Med. Res. Rev., 2003, 23, 488-518.
17. Lauring, A.S.; Andino, R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog., 2010, 6, e1001005.
18. Vignuzzi, M.; Stone, J.K.; Andino, R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res., 2005, 107, 173-181.
19. Gomez, J.; Martell, M.; Quer, J.; Cabot, B.; Esteban, J.I. Hepatitis C viral quasispecies. J. Viral. Hepat., 1999, 6, 3-16.
20. Neumann, A.U.; Lam, N.P.; Dahari, H.; Gretch, D.R.; Wiley, T.E.; Layden, T.J.; Perelson, A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 1998, 282, 103-107.
21. Biebricher, C.K.; Eigen, M. The error threshold. Virus Res., 2005, 107, 117-127.
22. Domingo, E. Viruses at the edge of adaptation. Virology, 2000, 270, 251-253.
23. Domingo, E. Antiviral strategy on the horizon. Virus Res., 2005, 107, 115-116.
24. Holland, J.J.; Domingo, E.; de la Torre, J.C.; Steinhauer, D.A. Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J. Virol., 1990, 64, 3960-3962.
25. Loeb, L.A.; Essigmann, J.M.; Kazazi, F.; Zhang, J.; Rose, K.D.; Mullins, J.I. Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc. Natl. Acad. Sci. USA, 1999, 96, 1492-1497.
26. Loeb, L.A.; Mullins, J.I. Lethal mutagenesis of HIV by mutagenic ribonucleoside analogs. AIDS Res. Hum. Retrovirus., 2000, 16, 1-3.
27. Sierra, S.; Davila, M.; Lowenstein, P.R.; Domingo, E. Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J. Virol., 2000, 74, 8316-8323.
28. Crotty, S.; Maag, D.; Arnold, J.J.; Zhong, W.; Lau, J.Y.; Hong, Z.; Andino, R.; Cameron, C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med., 2000, 6, 1375-1379.
29. Crotty, S.; Cameron, C.E.; Andino, R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA, 2001, 98, 6895-6900.
30. Contreras, A.M.; Hiasa, Y.; He, W.; Terella, A.; Schmidt, E.V.; Chung, R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol., 2002, 76, 8505-8517.
31. Asahina, Y.; Izumi, N.; Enomoto, N.; Uchihara, M.; Kurosaki, M.; Onuki, Y.; Nishimura, Y.; Ueda, K.; Tsuchiya, K.; Nakanishi, H.; Kitamura, T.; Miyake, S. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J. Hepatol., 2005, 43, 623-629.
32. Chevaliez, S.; Brillet, R.; Lazaro, E.; Hezode, C.; Pawlotsky, J.M. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol., 2007, 81, 7732-7741.
33. Hultgren, C.; Milich, D.R.; Weiland, O.; Sallberg, M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol., 1998, 79 (Pt 10), 2381-2391.
34. Parker, W.B. Metabolism and antiviral activity of ribavirin. Virus Res., 2005, 107, 165-171.
35. Cuevas, J.M.; Gonzalez-Candelas, F.; Moya, A.; Sanjuan, R. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol., 2009, 83, 5760-5764.
36. Rajewsky, K. Clonal selection and learning in the antibody system. Nature, 1996, 381, 751-758.
37. Gregorio, G.V.; Choudhuri, K.; Ma, Y.; Pensati, P.; Iorio, R.; Grant, P.; Garson, J.; Bogdanos, D.P.; Vegnente, A.; Mieli- Vergani, G.; Vergani, D. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin. Exp. Immunol., 2003, 133, 404-413.
38. Marceau, G.; Lapierre, P.; Beland, K.; Soudeyns, H.; Alvarez, F. LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? Hepatology, 2005, 42, 675-682.
39. Zhang, W.; Nardi, M.A.; Borkowsky, W.; Li, Z.; Karpatkin, S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood, 2009, 113, 4086-4093.
40. Hu, Y.W.; Rocheleau, L.; Larke, B.; Chui, L.; Lee, B.; Ma, M.; Liu, S.; Omlin, T.; Pelchat, M.; Brown, E.G. Immunoglobulin mimicry by Hepatitis C Virus envelope protein E2. Virology, 2005, 332, 538-549.
41. Taylor, D.R.; Shi, S.T.; Romano, P.R.; Barber, G.N.; Lai, M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science, 1999, 285, 107-110.
42. Garcia, M.A.; Gil, J.; Ventoso, I.; Guerra, S.; Domingo, E.; Rivas, C.; Esteban, M. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol. Mol. Biol. Rev., 2006, 70, 1032-1060.
43. Pavio, N.; Taylor, D.R.; Lai, M.M. Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J. Virol., 2002, 76, 1265-1272.
44. Cocquerel, L.; Voisset, C.; Dubuisson, J. Hepatitis C virus entry: potential receptors and their biological functions. J. Gen. Virol., 2006, 87, 1075-1084.
45. Burlone, M.E.; Budkowska, A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J. Gen. Virol., 2009, 90, 1055-1070.
46. Brazzoli, M.; Bianchi, A.; Filippini, S.; Weiner, A.; Zhu, Q.; Pizza, M.; Crotta, S. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J. Virol., 2008, 82, 8316-8329.
47. Mazzocca, A.; Sciammetta, S.C.; Carloni, V.; Cosmi, L.; Annunziato, F.; Harada, T.; Abrignani, S.; Pinzani, M. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J. Biol. Chem., 2005, 280, 11329-11339.
48. Machida, K.; Cheng, K.T.; Pavio, N.; Sung, V.M.; Lai, M.M. Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J. Virol., 2005, 79, 8079-8089.
49. Machida, K.; Kondo, Y.; Huang, J.Y.; Chen, Y.C.; Cheng, K.T.; Keck, Z.; Foung, S.; Dubuisson, J.; Sung, V.M.; Lai, M.M. Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein. J. Virol., 2008, 82, 6711-6720.
50. Wack, A.; Soldaini, E.; Tseng, C.; Nuti, S.; Klimpel, G.; Abrignani, S. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur. J. Immunol., 2001, 31, 166-175.
51. Crotta, S.; Stilla, A.; Wack, A.; D'Andrea, A.; Nuti, S.; D'Oro, U.; Mosca, M.; Filliponi, F.; Brunetto, R.M.; Bonino, F.; Abrignani, S.; Valiante, N.M. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med., 2002, 195, 35-41.
52. Frieder, D.; Larijani, M.; Tang, E.; Parsa, J.Y.; Basit, W.; Martin, A. Antibody diversification: mutational mechanisms and oncogenesis. Immunol. Res., 2006, 35, 75-88.
53. Longerich, S.; Basu, U.; Alt, F.; Storb, U. AID in somatic hypermutation and class switch recombination. Curr. Opin. Immunol., 2006, 18, 164-174.
54. Perez-Duran, P.; de Yebenes, V.G.; Ramiro, A.R. Oncogenic events triggered by AID, the adverse effect of antibody diversification. Carcinogenesis, 2007, 28, 2427-2433.
55. Landau, D.A.; Saadoun, D.; Calabrese, L.H.; Cacoub, P. The pathophysiology of HCV induced B-cell clonal disorders. Autoimmun. Rev., 2007, 6, 581-587.
56. Hassuna, N.; Monk, P.N.; Moseley, G.W.; Partridge, L.J. Strategies for targeting tetraspanin proteins: potential therapeutic applications in microbial infections. BioDrugs, 2009, 23, 341-359.
57. Poumbourios, P.; Drummer, H.E. Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents. Antivir. Chem. Chemother., 2007, 18, 169-189.
58. VanCompernolle, S.E.; Wiznycia, A.V.; Rush, J.R.; Dhanasekaran, M.; Baures, P.W.; Todd, S.C. Small molecule inhibition of hepatitis C virus E2 binding to CD81. Virology, 2003, 314, 371-380.
59. McHutchison, J.G.; Gordon, S.C.; Schiff, E.R.; Shiffman, M.L.; Lee, W.M.; Rustgi, V.K.; Goodman, Z.D.; Ling, M.H.; Cort, S.; Albrecht, J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med., 1998, 339, 1485-1492.
60. Teng, G.; Hakimpour, P.; Landgraf, P.; Rice, A.; Tuschl, T.; Casellas, R.; Papavasiliou, F.N. MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity, 2008, 28, 621-629.
61. Dorsett, Y.; McBride, K.M.; Jankovic, M.; Gazumyan, A.; Thai, T.H.; Robbiani, D.F.; Di Virgilio, M.; San-Martin, B.R.; Heidkamp, G.; Schwickert, T.A.; Eisenreich, T.; Rajewsky, K.; Nussenzweig, M.C. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity, 2008, 28, 630-638.
62. de Yebenes, V.G.; Belver, L.; Pisano, D.G.; Gonzalez, S.; Villasante, A.; Croce, C.; He, L.; Ramiro, A.R. miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J. Exp. Med., 2008, 205, 2199-2206.
63. Muramatsu, M.; Sankaranand, V.S.; Anant, S.; Sugai, M.; Kinoshita, K.; Davidson, N.O.; Honjo, T. Specific expression of activation- induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem., 1999, 274, 18470-18476.
64. Cohen, R.M.; Wolfenden, R. Cytidine deaminase from Escherichia coli. Purification, properties and inhibition by the potential transition state analog 3,4,5,6-tetrahydrouridine. J. Biol. Chem., 1971, 246, 7561-7565.
65. Samaranayake, M.; Bujnicki, J.M.; Carpenter, M.; Bhagwat, A.S. Evaluation of molecular models for the affinity maturation of antibodies: roles of cytosine deamination by AID and DNA repair. Chem. Rev., 2006, 106, 700-719.
66. Beale, R.C.; Petersen-Mahrt, S.K.; Watt, I.N.; Harris, R.S.; Rada, C.; Neuberger, M.S. Comparison of the differential contextdependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol., 2004, 337, 585-596.
67. Mountz, J.D.; Hsu, H.-C. Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases. Patent Application WO 2010/047698, April 29, 2010.
68. Jopling, C.L.; Yi, M.; Lancaster, A.M.; Lemon, S.M.; Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science, 2005, 309, 1577-1581.
69. Chang, J.; Nicolas, E.; Marks, D.; Sander, C.; Lerro, A.; Buendia, M.A.; Xu, C.; Mason, W.S.; Moloshok, T.; Bort, R.; Zaret, K.S.; Taylor, J.M. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol., 2004, 1, 106-113.
70. Lagos-Quintana, M.; Rauhut, R.; Yalcin, A.; Meyer, J.; Lendeckel, W.; Tuschl, T. Identification of tissue-specific microRNAs from mouse. Curr. Biol., 2002, 12, 735-739.
71. Esau, C.; Davis, S.; Murray, S.F.; Yu, X.X.; Pandey, S.K.; Pear, M.; Watts, L.; Booten, S.L.; Graham, M.; McKay, R.; Subramaniam, A.; Propp, S.; Lollo, B.A.; Freier, S.; Bennett, C.F.; Bhanot, S.; Monia, B.P. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab., 2006, 3, 87-98.
72. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with 'antagomirs'. Nature, 2005, 438, 685-689.
73. Norman, K.L.; Sarnow, P. Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. J. Virol., 84, 666-670.
74. Kapadia, S.B.; Barth, H.; Baumert, T.; McKeating, J.A.; Chisari, F.V. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J. Virol., 2007, 81, 374-383.
75. Wang, C.; Gale, M., Jr.; Keller, B.C.; Huang, H.; Brown, M.S.; Goldstein, J.L.; Ye, J. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol. Cell, 2005, 18, 425-434.
76. Jopling, C.L. Regulation of hepatitis C virus by microRNA-122. Biochem. Soc. Trans., 2008, 36, 1220-1223.
77. Jopling, C.L.; Schutz, S.; Sarnow, P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe, 2008, 4, 77-85.
78. Lanford, R.E.; Hildebrandt-Eriksen, E.S.; Petri, A.; Persson, R.; Lindow, M.; Munk, M.E.; Kauppinen, S.; Orum, H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science, 2010, 327, 198-201.
79. Choi, W.Y.; Giraldez, A.J.; Schier, A.F. Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR- 430. Science, 2007, 318, 271-274.
80. Norman, K.L.; Sarnow, P. Modulation of hepatitis C virus RNA abundance and the isoprenoid biosynthesis pathway by microRNA miR-122 involves distinct mechanisms. J. Virol., 2010, 84, 666-670.
81. Kurzynska-Kokorniak, A.; Jackowiak, P.; Figlerowicz, M.; Figlerowicz, M. Human- and virus-encoded microRNAs as potential targets of antiviral therapy. Mini. Rev. Med. Chem., 2009, 9, 927-937.
82. Love, T.M.; Moffett, H.F.; Novina, C.D. Not miR-ly small RNAs: big potential for microRNAs in therapy. J. Allergy Clin. Immunol., 2008, 121, 309-319.
83. Aigner, A. Delivery Systems for the Direct Application of siRNAs to Induce RNA Interference (RNAi) In Vivo. J. Biomed. Biotechnol., 2006, 2006, 71659